SCHEMBL30206049

SCHEMBL30206049

CNc1nc(Nc2ccc(N3CCOCC3)c(C#N)c2)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 5/20 0.40
▸ FLT3 P36888 3/20 0.36
▸ CDK2 P24941 3/20 0.36
▸ CDK1 P06493 2/20 0.36
▸ CCNB1 P14635 2/20 0.36
▸ CDK7 P50613 2/20 0.36
▸ CCNH P51946 2/20 0.36
▸ CCNE1 P24864 2/20 0.36
▸ MNAT1 P51948 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ ALK Q9UM73 3/20 0.36
▸ PKMYT1 Q99640 2/20 0.36
▸ RET P07949 2/20 0.36
▸ ROS1 P08922 2/20 0.36
▸ EML4 Q9HC35 2/20 0.36
▸ HPGD P15428 1/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ TNIK Q9UKE5 2/20 0.35
▸ MAPK10 P53779 2/20 0.35
▸ CCNT1 O60563 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29173387 1.00 LRRK2 (0.40) LRRK2FLT3CDK2CDK1CCNB1
SCHEMBL24944171 0.92 FLT3 (0.40) LRRK2FLT3CDK2CDK1CCNB1
SCHEMBL30206005 0.91 ALDH1A1 (0.41) LRRK2FLT3CDK2CDK1CCNB1
SCHEMBL29173373 0.91 ALDH1A1 (0.41) LRRK2FLT3CDK2CDK1CCNB1
SCHEMBL29173329 0.91 SYK (0.41) FLT3CDK2CCNE1ALKPKMYT1
SCHEMBL30206019 0.91 SYK (0.41) FLT3CDK2CCNE1ALKPKMYT1
SCHEMBL29173341 0.91 ALK (0.44) FLT3CDK2CCNE1ALKRET
SCHEMBL30206110 0.91 ALK (0.44) FLT3CDK2CCNE1ALKRET
SCHEMBL29173438 0.89 FLT3 (0.37) FLT3CDK2CCNE1ALKRET
SCHEMBL30206045 0.89 FLT3 (0.37) FLT3CDK2CCNE1ALKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 LRRK2 3283/4885FLT3 185/4885CDK2 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback